Online clinical pathway for managing adults with chronic kidney disease

Canadian Pharmacists Journal

Volumn 148, Issue 5, 2015, Pages 257-262

  Curtis, Craig ^a   Balint, Carlee ^b   Al Hamarneh, Yazid N ^c   Donald, Maoliosa ^d   Tsuyuki, Ross T ^c,f   McBrien, Kerry ^d,e   Jackson, Wes ^e   Hemmelgarn, Brenda ^d,e  

^a Alberta Health Services   (United Kingdom)

^b FOOTHILLS HOSPITAL   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT;

ALBUMINURIA; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL PATHWAY; DRUG INFORMATION; GLOMERULUS FILTRATION; HUMAN; LIFESTYLE; PRACTICE GUIDELINE; REVIEW; SCORING SYSTEM; URINALYSIS;

EID: 84940925457     PISSN: 17151635     EISSN: 1913701X     Source Type: Journal    
DOI: 10.1177/1715163515597243     Document Type: Review

References (39)

1. P.AroraP.VasaD.Brenner. Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ2013;185:E417-23.
2. T.H.JafarC.H.SchmidM.Landa. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med2001;135:73-87.
3. E.J.LewisL.G.HunsickerW.R.Clarke. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med2001;345:851-60.
4. J.T.WrightJrG.BakrisT.GreeneL.Y.AgodoaEffect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA2002;288:2421-31.
5. M.TonelliL.MoyeF.M.Sacks. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol2003;14:1605-13.
6. J.F.E.MannH.C.GersteinJ.Pogue. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med2001;134:629-36.
7. D.E.WeinerH.TighiouartM.G.AminChronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol2004;15:1307-15.
8. M.ShlipakP.HeidenreichAssociation of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med2002;137:555-62.
9. M.TonelliC.BohmS.PandeyaJ.GillCardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis2001;37:484-9.
10. L.StevensG.FaresJ.FlemingLow rates of testing and diagnostic codes usage in a commercial clinical laboratory: evidence for lack of physician awareness of chronic kidney disease. J Am Soc Nephrol2005;16:2439-48.
11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl2013;3:1-150.
12. T.RotterL.KinsmanE.James. Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. Cochrane Database Syst Rev2010;(3):CD006632.
13. D.AllenE.GillenL.RixsonSystematic review of the effectiveness of integrated care pathways: what works, for whom, in which circumstances?Int J Evid Based Healthc2009;7:61-74.
14. D.SulchI.PerezA.MelbournL.KalraRandomized controlled trial of integrated (managed) care pathway for stroke rehabilitation. Stroke2000;31:1929-34.
15. S.CunninghamC.LoganL.Lockerbie. Effect of an integrated care pathway on acute asthma/wheeze in children attending hospital: cluster randomized trial. J Pediatr2008;152:315-20.
16. Canadian Pharmacists Association. Pharmacists’ expanded scope of practice in Canada. 2014. Available: www.pharmacists.ca/index.cfm/pharmacy-in-canada/scope-of-practice-canada/ (accessed December 5, 2014).
17. Alberta College of Pharmacists. The health professional’s guide to pharmacist prescribing. 2012. Available: https://pharmacists.ab.ca/sites/default/files/HPGuidePrescribing.pdf (accessed December 5, 2014).
18. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl2013;3:1-305.
19. S.TobeJ.StoneM.Brouwers. Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative. CMAJ2011;183:1135-50.
20. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. Can J Diabetes2013; 37(Suppl 1):S1-212.
21. J.-F.TanguayA.D.BellM.L.Ackman. Focused 2012 update of the Canadian Cardiovascular Society Guidelines for the use of antiplatelet therapy. Can J Cardiol2013;29:1334-45.
22. T.J.AndersonJ.GrégoireR.A.Hegele. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol2013;29:151-67.
23. D.G.HackamR.R.QuinnP.Ravani. The 2013 Canadian Hypertension Education Program (CHEP) recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol2013;29:528-42.
24. AHS Laboratory Services. Use of the CKD-EPI equation for reporting estimated glomerular filtration rate. 2013. Available: www.albertahealthservices.ca/LabServices/wf-lab-bulletin-use-of-ckd-epi-equation-egfr-final.pdf (accessed December 5, 2014).
25. S.YusufK.K.TeoJ.Pogue. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med2008;358:1547-59.
26. K.MatsushitaM.van der VeldeB.C.Astor. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet2010;375:2073-81.
27. B.R.HemmelgarnB.J.MannsA.Lloyd. Relation between kidney function, proteinuria, and adverse outcomes. JAMA2010;303:423-9.
28. M.T.JamesB.R.HemmelgarnM.TonelliEarly recognition and prevention of chronic kidney disease. Lancet2010;375:1296-309.
29. M.TonelliP.MuntnerA.Lloyd. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med2011;154:12-21.
30. G.F.M.StrippoliM.CraigJ.J.Deeks. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ2004;329:828-39.
31. A.S.LeveyP.E.de JongJ.Coresh. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int2011;80:17-28.
32. Chronic kidney disease (CKD) management in general practice. 2nd ed.Melbourne (AU): Kidney Health Australia; 2012.
33. S.SaidG.T.HernandezThe link between chronic kidney disease and cardiovascular disease. J Nephropathol2014;3:99-104.
34. M.J.JardineT.NinomiyaV.Perkovic. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol2010;56:956-65.
35. N.PannuM.K.NadimAn overview of drug-induced acute kidney injury. Crit Care Med2008;36(4 Suppl):S216-23.
36. C.NaughtonDrug-induced nephrotoxicity. Am Fam Physician2008;78:743-50.
37. A.FaragA.X.GargL.LiA.K.JainDosing errors in prescribed antibiotics for older persons with CKD: a retrospective time series analysis. Am J Kidney Dis2014;63:422-8.
38. G.R.AronoffJ.R.Aronoff. Drug prescribing in kidney disease: can’t we do better?Am J Kidney Dis2014;63:382-3.
39. M.MunarH.SinghDrug dosing adjustments in patients with chronic kidney disease. Am Fam Physician2007;75:1487-96.